WW International Inc. logo

WW International Inc. (WW)

Market Closed
1 Sep, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
16. 33
-0.36
-2.157%
$
163.78M Market Cap
- P/E Ratio
0.59% Div Yield
289,466 Volume
-0.08 Eps
$ 16.69
Previous Close
Add Transaction
Day Range
15.64 16.93
Year Range
8.37 38.38
Want to track WW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
More turnover at the top, but this bull still believes in the Weight Watchers parent

More turnover at the top, but this bull still believes in the Weight Watchers parent

D.A. Davidson reckons WW is a buy as its customers need more than a prescription.

Marketwatch | 1 year ago
Here's Why WW International (WW) is Poised for a Turnaround After Losing -26.67% in 4 Weeks

Here's Why WW International (WW) is Poised for a Turnaround After Losing -26.67% in 4 Weeks

The heavy selling pressure might have exhausted for WW International (WW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks | 1 year ago
WW International, Inc. (WW) Q3 2024 Earnings Call Transcript

WW International, Inc. (WW) Q3 2024 Earnings Call Transcript

WW International, Inc. (NASDAQ:WW ) Q3 2024 Results Conference Call November 6, 2024 8:30 AM ET Company Participants David Helderman - Vice President, Investor Relations Tara Comonte - Interim President & Chief Executive Officer Heather Stark - Chief Financial Officer Donna Boyer - Chief Product Officer Conference Call Participants Nathan Feather - Morgan Stanley Alex Fuhrman - Craig-Hallum Capital Group Karru Martinson - Jefferies Henry Carr - UBS Operator Good day, and welcome to the WW International Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.

Seekingalpha | 1 year ago
WW International (WW) Beats Q3 Earnings and Revenue Estimates

WW International (WW) Beats Q3 Earnings and Revenue Estimates

WW International (WW) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.06 per share a year ago.

Zacks | 1 year ago
WW Stock Rises as WeightWatchers Expands Drug Offerings

WW Stock Rises as WeightWatchers Expands Drug Offerings

Shares of WW International Inc (WW, Financial) soared by 43.09% today due to the company's strategic move to expand its clinical weight management services. This expansion includes the introduction of compounded semaglutide, which offers a cost-effective and accessible alternative to popular medications like Ozempic and Wegovy, particularly during the current supply shortages.

Gurufocus | 1 year ago
WW International (WW) Surges After Adding Semaglutide to Weight Loss Program

WW International (WW) Surges After Adding Semaglutide to Weight Loss Program

WW International (WW, Financial) experienced a significant stock price increase, soaring 20.7% to $1.40. Early trading saw the stock rise as much as 46.5%.

Gurufocus | 1 year ago
WW International (WW) Surges After Introducing Compounded Semaglutide to Weight Loss Plans

WW International (WW) Surges After Introducing Compounded Semaglutide to Weight Loss Plans

WW International (WW, Financial), a provider of weight loss solutions, experienced a significant stock movement with an initial surge of over 46.5%, which later narrowed to around a 25% increase, reaching $1.45. This follows a nearly 47% rise in the previous trading session.

Gurufocus | 1 year ago
WeightWatchers Stock Soars on Copycat Weight-Loss Drug Offering

WeightWatchers Stock Soars on Copycat Weight-Loss Drug Offering

Shares of WW International (WW), better known as WeightWatchers, jumped nearly 25% Tuesday when the dieting services company announced it is offering a copycat version of blockbuster weight-loss drugs.

Investopedia | 1 year ago
WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program

WeightWatchers adds compounded version of Novo's obesity drug to weight-loss program

WeightWatchers said on Tuesday it is adding a compounded version of Novo Nordisk's obesity drug Wegovy to its weight-management programs.

Reuters | 1 year ago
WeightWatchers CEO Sima Sistani out in abrupt exit, embraced weight loss drugs

WeightWatchers CEO Sima Sistani out in abrupt exit, embraced weight loss drugs

WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte has stepped in to serve as interim CEO.

Foxbusiness | 1 year ago
WeightWatchers CEO suddenly quits after push to embrace weight-loss drugs like Ozempic, Wegovy

WeightWatchers CEO suddenly quits after push to embrace weight-loss drugs like Ozempic, Wegovy

Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.

Nypost | 1 year ago
WeightWatchers CEO Sima Sistani is leaving the company

WeightWatchers CEO Sima Sistani is leaving the company

WeightWatchers CEO Sima Sistani is leaving the company after two and a half years. During that time, the company has radically altered its business model to stay competitive in the Ozempic era.

Fastcompany | 1 year ago
Loading...
Load More